Skip to main content

Table 2 Factors associated with completion of therapy

From: Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine

  Not Completed Completed Unadjusted Adjusted
  n percent n percent RR 95% CI p-value RR 95% CI p-value
Type of Therapya,b           
 Isoniziad + Rifpaentine 13 14.9 74 85.1 Reference Reference
 Rifampin only 12 14.6 70 85.4 1.00 0.88, 1.14 0.96 0.88 0.55, 1.38 0.57
 Isoniazid only 107 48.2 115 51.8 0.61 0.52, 0.71 <0.001 0.58 0.36, 0.93 0.02
 Isoniazid only (vs rifampin only)      0.61 0.52, 0.71 <0.001 0.66 0.56, 0.79 <0.001
Clinicb,c           
 Public Health 59 22.5 203 77.5 Reference Reference
 Employee Health 20 74.1 7 25.9 0.33 0.18, 0.64 <0.001 0.37 0.20, 0.69 <0.01
 International 37 54.4 31 45.6 0.59 0.45, 0.77 <0.001 0.64 0.47, 0.85 <0.01
 Homeless 9 52.9 8 47.1 0.61 0.37, 1.01 0.06 0.65 0.38, 1.09 0.10
 Infectious Diseases 7 41.2 10 58.8 0.76 0.51, 1.14 0.18 0.74 0.48, 1.12 0.16
Type of monitoringa,c           
 Weekly DOT/phone calls 13 15.1 73 84.9 Reference Reference
 Monthly clinic visits 38 27.3 101 72.7 0.86 0.75, 0.98 0.03 1.12 0.71, 1.76 0.62
 Less often 81 48.8 85 51.2 0.60 0.51, 0.72 <0.001 1.21 0.75, 1.96 0.43
Side effectsc 37 28.2 94 71.8 1.13 0.98, 1.30 0.09 1.03 0.90, 1.18 0.66
Number of other medical problemsa,d          
 0 47 26.6 130 73.5 Reference Reference
 1-2 42 35.3 77 64.7 0.88 0.75, 1.03 0.12 1.00 0.84, 1.19 1.00
 3+ 43 45.3 52 54.7 0.75 0.61, 0.91 0.01 1.08 0.88, 1.33 0.47
  1. Abbreviations: RR Relative Risk, 95% CI 95% Confidence Interval
  2. a Adjusted for clinic type
  3. b Adjusted for type of monitoring
  4. c Adjusted for treatment
  5. d Adjusted for insurance